Biodesix Plunges 11.63% on Q2 Loss, Revenue Surprise

On August 8, 2025, Biodesix's stock experienced a significant drop of 11.63% in pre-market trading, reflecting investor concerns and market sentiment.

Biodesix reported a net loss of $11.5 million for the second quarter of 2025, marking a 6% increase in losses compared to the same period last year. The company's adjusted EBITDA also showed a loss of $7.2 million, indicating ongoing financial challenges.

Despite the financial setbacks, Biodesix's revenue growth has been notable. The company reported a revenue surprise of +7.34% for the quarter ended June 2025, suggesting that its diagnostic solutions are gaining traction in the market. This revenue growth is a positive sign for the company's long-term prospects, as it indicates increasing demand for its products and services.

Analysts have maintained a neutral stance on Biodesix's stock. William Blair analyst Andrew Brackmann has given a Hold rating on August 5, reflecting a cautious outlook on the company's future performance. This rating is based on the company's current financial situation and the potential for future growth.